Nucleus Projects 14.3-Point IQ Gap Among Embryos
The IVF screening company's projections, which it says rely on training data from about 500,000 people, have drawn a recommendation from an advertising watchdog.
Updated on Nov. 8, 2026 in Life Sciences
Live Poll
Would you support using genetic screening to select embryos based on predicted intelligence?
Nucleus Genomics projects a 14.3-point difference between the highest and lowest intelligence scores among 10 IVF embryos, according to the company's Vitruvian models. The National Advertising Division has recommended the company stop implying its IVF+ service can identify the smartest embryo.
Why it matters
The claims concern commercial genetic screening of embryos created through in vitro fertilization, a practice that the American Society for Reproductive Medicine's committees have said remains unproven for polygenic screening. The dispute highlights the gap between projected gains and the scientific evidence supporting them.
Nucleus's intelligence score was trained on association data from about 500,000 people and evaluated on about 40,000 European-ancestry siblings in the UK Biobank. The company's projections are modeled rather than observed outcomes, and the extraction does not report any validation of predicted embryo rankings against later measured IQ.
The players
Nucleus Genomics
A genetics company offering the Vitruvian embryo-scoring models and the IVF+ service, which the National Advertising Division has advised against marketing as identifying the smartest embryo.
National Advertising Division
The advertising self-regulatory body that recommended Nucleus Genomics stop implying its IVF+ service can identify the smartest embryo.
The details
Vitruvian scores embryos already created through in vitro fertilization to help parents choose one for implantation, and the models do not edit DNA. Nucleus's IQ estimate uses results from the UK Biobank's verbal-numerical reasoning test.
Timeline
2019: A study estimated an average gain of about 2.5 IQ points when screening five viable embryos.
December 2025: ASRM committees said polygenic embryo screening was unproven.
November 8, 2026: Nucleus projected the 14.3-point IQ gap among 10 embryos.
The Big Picture
The company's projections are an order of magnitude above the roughly 2.5-point average gain estimated in a 2019 study of screening five viable embryos. The gap between those figures is central to the advertising dispute and to the professional societies' position that polygenic screening remains unproven.
Prospective parents using IVF may face choices about whether to pay for polygenic embryo screening, and the advertising ruling suggests claims about selecting the smartest embryo are under scrutiny. The extraction does not establish how much the service costs or how it would be offered to patients.
The takeaway
Projected differences among embryos can be substantial on paper while the underlying predictive evidence remains limited, so claims about selecting the smartest embryo warrant careful scrutiny before reliance.
Further reading
Explore more in Life Sciences to see how embryo screening and genetic prediction fit into the broader research field.
Source note: This article includes information reported by TokenPost.
Live Poll
Would you support using genetic screening to select embryos based on predicted intelligence?
